Mr. Farman’s practice focuses on corporate, securities and investment transactions, with a particular emphasis on public and private securities offerings, private equity fund formation and investments, venture capital financings of emerging-growth companies, mergers and acquisitions, federal securities law compliance, and general corporate and securities counseling of public and private companies. He is a member of the firm's Corporate Department and co-chair of the firm’s global Private Equity Fund Group.
Mr. Farman has significant expertise in the private equity fund area, and regularly advises general partners, institutional investors, and investment advisers in connection with the formation of venture capital, buyout and other private equity funds. He has represented institutional investors in the formation of over 300 domestic and foreign private equity funds, including many of the largest private equity funds ever formed. He has also represented general partners in the formation of over 40 private equity funds and funds-of-funds.
Mr. Farman received his B.A. degree from Stanford University in 1981. He received his J.D. from the University of California, Davis, School of Law, in 1985, where he was Editor of the U.C. Davis Law Review. From 1985 to 1986, Mr. Farman was a Judicial Clerk to Judge Harry Pregerson, United States Court of Appeals for the Ninth Circuit.
Mr. Farman has been recognized by his peers as one of Best Lawyers in America (2007-2014). He has lectured and written extensively on private equity matters and a variety of other corporate and securities topics.
American Pharmaceutical Partners $4.1 billion Acquisition
Represented American Pharmaceutical Partners, a public pharmaceutical company, in its $4.1 billion acquisition of privately-held American Bioscience.
American Pharmaceutical Partners $160 million IPO
Represented American Pharmaceutical Partners in its $160 million initial public offering. Prior to the IPO, Mr. Farman represented APP in its $52 million Series A-D preferred stock financings, its $75 million acquisition of a generic pharmaceutical company, and various other equity and debt financings, business acquisitions, and strategic collaborations.
Abraxis Bioscience $2 billion Spin-Off
Represented Abraxis Bioscience, a public company, in the spin-off of a new $2 billion public company focused on biopharmaceuticals.
OSI $700 million Acquisition by Agilent
Represented Objective Systems Integrators, a public telecommunications software company, in a $700 million cash tender offer acquisition by Agilent Technologies.
Marrone Bio $60 million IPO and $42million follow-on
Represented Marrone Bio Innovations, Inc., a biopesticide company in its $60 million initial public offering and its subsequent $42 million primary/secondary follow-on offering.
Private Equity Funds - Investors
Represented institutional investors in the formation of over 400 domestic and foreign private equity funds, with per-investor commitments ranging from $5 million to $600 million. In the last three years alone, Mr. Farman has represented limited partner investors in their investment of more than $10 billion in over 50 funds having an aggregate committed capital in excess of $200 billion.
Private Equity Funds – General Partners
Represented general partners/fund managers in the formation of over 50 private equity funds and funds-of-funds with aggregate capital in excess of $10 billion.
Financings of Emerging Growth Companies
Represented venture capital funds, other institutional investors, and various start-up and emerging-growth technology companies, in over 50 preferred stock financings and other private equity investments.